Combating COVID-19 with mesenchymal stem cell therapy.
COVID-19
Cytokines
Immunomodulatory
Mesenchymal stem cells
SARS-CoV-2
Journal
Biotechnology reports (Amsterdam, Netherlands)
ISSN: 2215-017X
Titre abrégé: Biotechnol Rep (Amst)
Pays: Netherlands
ID NLM: 101637426
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
29
04
2020
revised:
09
05
2020
accepted:
10
05
2020
pubmed:
19
5
2020
medline:
19
5
2020
entrez:
19
5
2020
Statut:
epublish
Résumé
The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients.
Identifiants
pubmed: 32420049
doi: 10.1016/j.btre.2020.e00467
pii: S2215-017X(20)30363-5
pii: e00467
pmc: PMC7224671
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e00467Informations de copyright
© 2020 Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Stem Cells. 2008 Jan;26(1):279-89
pubmed: 17962701
Cell. 2018 Jan 25;172(3):423-438.e25
pubmed: 29249360
Stem Cell Rev Rep. 2019 Apr;15(2):166-175
pubmed: 30623359
Lancet. 2020 Mar 21;395(10228):931-934
pubmed: 32164834
Annu Rev Virol. 2014 Nov 1;1:261-283
pubmed: 25599080
Thorax. 2014 Sep;69(9):819-25
pubmed: 24891325
Stem Cells Transl Med. 2018 Aug;7(8):615-624
pubmed: 29737632
Stem Cells. 2010 Dec;28(12):2229-38
pubmed: 20945332
Med Drug Discov. 2020 Mar;5:100019
pubmed: 32296777
Am J Respir Crit Care Med. 2015 Aug 1;192(3):324-36
pubmed: 26067592
PLoS One. 2010 Apr 26;5(4):e10088
pubmed: 20436665
World J Stem Cells. 2014 Nov 26;6(5):526-39
pubmed: 25426250
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Emerg Microbes Infect. 2018 Sep 12;7(1):154
pubmed: 30209269
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
Cell Stem Cell. 2009 Jul 2;5(1):54-63
pubmed: 19570514
Curr Stem Cell Res Ther. 2019;14(1):22-33
pubmed: 30210006
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):139-144
pubmed: 32057211
Am J Respir Crit Care Med. 2013 Apr 1;187(7):751-60
pubmed: 23292883
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152